health · HHS-NIH11
Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
National Institutes of Health · PAR-27-125
Deadline
TBD
GRANTQUICK SUMMARYPlain-English Overview
Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required). National Institutes of Health. The NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to develop and implement investigator-initiated multi-site clinical trials, including efficacy, effectiveness, pragmatic, and/or implementation research clinical trials.... Funding amounts not specified.
Who Should Apply
Nonprofits (non-501c3), For-profit organizations, Public universities/colleges, Independent school districts, Other eligible entities (+10 more)
Who Should NOT Apply
Organizations not matching the eligible applicant types listed above
Key Requirements (Plain English)
- •Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U
💡 GrantQuick Tip
Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.
Competitiveness: Moderate to high — federal grants are always competitive
What This Grant Funds
The NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to develop and implement investigator-initiated multi-site clinical trials, including efficacy, effectiveness, pragmatic, and/or implementation research clinical trials. Applications that propose a large and/or complex clinical trial conducted at either a single site or at multiple locations but without physical clinical sites (e.g., decentralized or virtual trials) may also be eligible. Proposed trials must be relevant to the research mission of the participating ICs and meet the NIH definition of a clinical trial (see NOT-OD-15-015 and NOT-OD-26-032). The objective of the application is to present 1) the scientific rationale as well as a comprehensive scientific and operational plan for the trial, and 2) a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase up to 2 years (UG3) and a full enrollment and clinical trial implementation phase up to 5 years (UH3), for a total award duration of up to 7 years. A UG3 project that meets its milestones will be administratively considered for transition to the UH3 award. Investigators with expertise and insights into this area are encouraged to begin to consider applying for this NOFO.
Who Can Apply
Eligible Applicant Types
Funding Details
- Cost Sharing Required?
- No
- Funding Instrument
- cooperative_agreement
Key Dates
Agency Contact
National Heart, Lung, and Blood Institute (NHLBI) Please contact via e-mail.
NHLBIDCVSClinical@mail.nih.govReady to apply?
View the full NOFO and submit your application on Grants.gov